Replek Overview
- Founded
-
1945
- Status
-
Public
- Employees
-
479
- Stock Symbol
-
REPL
- Share Price
-
$1.44K
- (As of Friday Closing)
Replek General Information
Description
Replek AD is engaged in the development, design and production of generic medicines. The company develops drugs in different pharmaceutical therapeutic categories including anti-platelet, lipid-lowering, atypical antipsychotic, anti-infective, among others. It manufactures drugs in different forms including tablets, capsules, oral solutions, creams and ointments. Its product portfolio consists of Clopidogrel, Atorvastatin, Simvastatin, risperidone, Clarythromycin, Ciprofloxacin, Meloksikam, Risperidon, terazosin, among others. Replek also offers cannabis oil products, food supplements and cosmetics.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Other Devices and Supplies
Distributors/Wholesale
Stock Exchange
XMAE
Primary Office
- Kozle st. 188
- Skopje, 1000
- Macedonia
+389 02 000 0000
Replek Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.44K | $1.47K | $1.39K - $2.04K | $37.4M | 25.9K | 10.00 | $42.47 |
Replek Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 39,290 | 50,207 | 37,167 | |
| Revenue | 22,239 | 23,892 | 23,322 | 18,942 |
| EBITDA | 2,279 | 3,265 | 3,648 | 2,796 |
| Net Income | 1,101 | 2,565 | 3,003 | 2,418 |
| Total Assets | 35,748 | 38,688 | 41,948 | 34,637 |
| Total Debt | 2,912 | 3,455 | 3,944 | 1,892 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Replek Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
